ArticleTalanta2021
A multi-target lateral flow immunoassay enabling the specific and sensitive detection of total antibodies to SARS COV-2.
Article in Talanta, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 84 citations in OpenAlex.
- A systematic review of the advancement on colorimetric nanobiosensors for SARS-CoV-2 detection.Journal of pharmaceutical and biomedical analysis · 2023Pooled it
- Updating the use of nano-biosensors as promising devices for the diagnosis of coronavirus family members: A systematic review.Journal of pharmaceutical and biomedical analysis · 2022Pooled it
- Peroxidase-Mimicking Nanozymes for Rapid Detection of Infectious Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Evolving Landscape of Emerging Virus Diagnosis: Challenges and Innovations.Molecular biotechnology · 2026Review
- Flow cytometric analysis of the SARS coronavirus 2 antibodies in human plasma.Scientific reports · 2025Article
- Sensitive Colorimetric Lateral Flow Assays Enabled by Platinum-Group Metal Nanoparticles with Peroxidase-Like Activities.Advanced healthcare materials · 2025Article
- SARS-CoV-2 exposure in hunting and stray dogs of southern Italy.Veterinary research communications · 2024Article
- The evolution of immune profiling: will there be a role for nanoparticles?Nanoscale horizons · 2024Review
- Au@Pt nanoparticles-based signal-enhanced lateral flow immunoassay for ultrasensitive naked-eye detection of SARS-CoV-2.Mikrochimica acta · 2024Article
- Efficiency of recombinant Ybgf in a double antigen-ELISA for the detection of Coxiella antibodies in ruminants.Veterinary and animal science · 2024Article
- Development and application of a colloidal-gold immunochromatographic strip for detecting Getah virus antibodies.Applied microbiology and biotechnology · 2024Article
- Development and evaluation of a Lateral flow immunoassay (LFIA) prototype for the detection of IgG anti-SARS-CoV-2 antibodies.Heliyon · 2024Article
- Recent Advances in Lateral Flow Assays for Viral Protein Detection with Nanomaterial-Based Optical Sensors.Biosensors · 2024Review
- Detection ofJournal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc · 2023Article
- Performance evaluation of in-house developed Covid-19 IgG/IgM antibody rapid diagnostic kit.AMB Express · 2023Article
- Recent Advances in Quantum Dot-Based Lateral Flow Immunoassays for the Rapid, Point-of-Care Diagnosis of COVID-19.Biosensors · 2023Review
- Comparison of Three Lateral Flow Immunoassay Formats for the Detection of Antibodies against the SARS-CoV-2 Antigen.Biosensors · 2023Article
- Diagnostics and analysis of SARS-CoV-2: current status, recent advances, challenges and perspectives.Chemical science · 2023Review
- Nano-biosensor for SARS-CoV-2/COVID-19 detection: methods, mechanism and interface design.RSC advances · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A rapid test for detecting total immunoglobulins directed towards the nucleocapsid protein (N) of severe acute syndrome coronavirus 2 (SARS CoV-2) was developed, based on a multi-target lateral flow immunoassay comprising two test lines. Both test lines bound to several classes of immunoglobulins (G, M, and A). Specific anti-SARS immunoglobulins were revealed by a colorimetric probe formed by N and gold nanoparticles. Targeting the total antibodies response to infection enabled achieving 100% diagnostic specificity (95.75-100, C.I. 95%, n = 85 healthy and with other infections individuals) and 94.6% sensitivity (84.9-98.9, C.I. 95%, n = 62 SARS CoV-2 infected subjects) as early as 7 days post confirmation of positivity. Agreeing results with a reference serological ELISA were achieved, except for the earlier detection capability of the rapid test. Follow up of the three seroconverting patients endorsed the hypothesis of the random rise of the different immunoglobulins and strengthened the 'total antibodies' approach for the trustworthy detection of serological response to SARS CoV-2 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.